Abstract
Psoriatic arthritis (PsA) affects up to 30% patients with skin psoriasis and is characterized by immune-mediated synovio-entheseal inflammation. Clinical presentation is diverse and can lead to joint destruction and deformities in 50% of patients with PsA. With better understanding of pathogenesis of the disease, various disease-modifying targeted therapies have emerged in the recent decades. So early recognition of PsA is crucial as initiation of therapy targeted to achieve minimal disease activity can lead to significant improvement in joint symptoms and quality of life.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:2095–6. https://doi.org/10.1056/NEJMc1704342.
Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–7. https://doi.org/10.1136/ard.2004.032482.
Coates LC, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386:2489–98. https://doi.org/10.1016/s0140-6736(15)00347-5.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41:545–68. https://doi.org/10.1016/j.rdc.2015.07.001.
Eder L, et al. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken). 2011;63:619–22. https://doi.org/10.1002/acr.20401.
Egeberg A, et al. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann Rheum Dis. 2017;76:1591–7. https://doi.org/10.1136/annrheumdis-2016-210963.
Mease PJ, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–35. https://doi.org/10.1016/j.jaad.2013.07.023.
Gottlieb AB, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat. 2006;17:279–87. https://doi.org/10.1080/09546630600823369.
Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151–8. https://doi.org/10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T.
Rosen CF, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012;51:571–6. https://doi.org/10.1093/rheumatology/ker365.
Tillett W, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54:157–62. https://doi.org/10.1093/rheumatology/keu264.
Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35:680–9.
Coates LC, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–71. https://doi.org/10.1002/art.39573.
McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):9–13. https://doi.org/10.1111/j.1468-3083.2009.03363.x.
Dalbeth N, et al. Nail disease in psoriatic arthritis: distal phalangeal bone edema detected by magnetic resonance imaging predicts development of onycholysis and hyperkeratosis. J Rheumatol. 2012;39:841–3. https://doi.org/10.3899/jrheum.111118.
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)–an analysis of 220 patients. Q J Med. 1987;62:127–41.
Karim Z, et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum. 2004;50:387–94. https://doi.org/10.1002/art.20054.
Wakefield RJ, et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis. 2004;63:382–5.
Gelfand JM, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–41. https://doi.org/10.1001/jama.296.14.1735.
Ogdie A, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–32. https://doi.org/10.1136/annrheumdis-2014-205675.
Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2017;69:51–7. https://doi.org/10.1002/acr.23094.
Horreau C, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12–29. https://doi.org/10.1111/jdv.12163.
Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23:561–5. https://doi.org/10.1111/j.1468-3083.2008.03031.x.
Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis. 2013;72:1200–5. https://doi.org/10.1136/annrheumdis-2012-202143.
Egeberg A, et al. Association of psoriatic disease with uveitis: a Danish Nationwide Cohort Study. JAMA Dermatol. 2015;151:1200–5. https://doi.org/10.1001/jamadermatol.2015.1986.
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–5. https://doi.org/10.1001/archdermatol.2010.186.
McDonough E, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41:887–96. https://doi.org/10.3899/jrheum.130797.
Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 2):ii37–9; discussion ii40–31. https://doi.org/10.1136/ard.2004.030775.
Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201.
Liu Y, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4:e1000041. https://doi.org/10.1371/journal.pgen.1000041.
Bowes J, et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun. 2015;6:6046. https://doi.org/10.1038/ncomms7046.
Bowes J, et al. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Ann Rheum Dis. 2015;74:1882–5. https://doi.org/10.1136/annrheumdis-2014-207187.
Stankler L. An experimental investigation on the site of skin damage inducing the Koebner reaction in psoriasis. Br J Dermatol. 1969;81:534–5.
Tinazzi I, et al. ‘Deep Koebner’ phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Ann Rheum Dis. 2018;77:922–5. https://doi.org/10.1136/annrheumdis-2017-212681.
Thorarensen SM, et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2017;76:521–5. https://doi.org/10.1136/annrheumdis-2016-209334.
Ogdie A, Gelfand JM. Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need. Arch Dermatol. 2010;146:785–8. https://doi.org/10.1001/archdermatol.2010.136.
Sherlock JP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4−CD8− entheseal resident T cells. Nat Med. 2012;18:1069–76. https://doi.org/10.1038/nm.2817.
Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496–502. https://doi.org/10.1016/j.autrev.2014.01.050.
Yang L, et al. Augmented Th17 differentiation leads to cutaneous and synovio-entheseal inflammation in a novel model of psoriatic arthritis. Arthritis Rheumatol. 2018;70:855–67. https://doi.org/10.1002/art.40447.
Scher JU, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67:128–39. https://doi.org/10.1002/art.38892.
Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70:2152–4. https://doi.org/10.1136/ard.2011.150938.
Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–50. https://doi.org/10.1136/annrheumdis-2013-204858.
Kingsley GH, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368–77. https://doi.org/10.1093/rheumatology/kes001.
Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016;43:356–61. https://doi.org/10.3899/jrheum.150614.
Cutolo M, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724–34. https://doi.org/10.3899/jrheum.151376.
Edwards CJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065–73. https://doi.org/10.1136/annrheumdis-2015-207963.
Antoni C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–7. https://doi.org/10.1136/ard.2004.032268.
Kavanaugh A, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86. https://doi.org/10.1002/art.24403.
Mease PJ, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89. https://doi.org/10.1002/art.21306.
Mease PJ, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55. https://doi.org/10.1136/annrheumdis-2013-203696.
Mease PJ, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–72. https://doi.org/10.1002/art.20335.
McInnes IB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–9. https://doi.org/10.1016/S0140-6736(13)60594-2.
Mease PJ, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87. https://doi.org/10.1136/annrheumdis-2016-209709.
McInnes IB, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–46. https://doi.org/10.1016/S0140-6736(15)61134-5.
Hodge JA, et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318–28.
Mease P, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–50. https://doi.org/10.1056/NEJMoa1615975.
Mease P, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939–48. https://doi.org/10.1002/art.30176.
Mease PJ, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76:1550–8. https://doi.org/10.1136/annrheumdis-2016-210724.
Asiri A, Thavaneswaran A, Kalman-Lamb G, Chandran V, Gladman DD. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol. 2014;32:728–31.
Kaltwasser JP, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939–50. https://doi.org/10.1002/art.20253.
Clegg DO, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2013–20.
Gupta AK, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995;22:894–8.
van der Heijde D, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56:2698–707. https://doi.org/10.1002/art.22805.
Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–8. https://doi.org/10.1093/rheumatology/keg384.
Gladman DD, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12:R113. https://doi.org/10.1186/ar3049.
Araujo EG, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis. 2015;74:655–60. https://doi.org/10.1136/annrheumdis-2013-204229.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Malik, F., Haberman, R., Scher, J.U. (2020). Psoriatic Arthritis. In: Efthimiou, P. (eds) Absolute Rheumatology Review. Springer, Cham. https://doi.org/10.1007/978-3-030-23022-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-23022-7_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-23021-0
Online ISBN: 978-3-030-23022-7
eBook Packages: MedicineMedicine (R0)